. . .

Keep Your Eyes on This Stock: Celgene Corporation (NASDAQ: CELG)

Celgene Corporation (NASDAQ: CELG) stock observed trading -0.58% off 52-week high price. On the other end, the stock has been noted 64.72% away from low price over the last 52-weeks. The stock disclosed a move of 1.68% away from 50 day moving average and 13.08% away from 200 day moving average. Moving closer, we can see that shares have been trading 1.23% off 20-day moving average. It has market cap of $68015.42M .

Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced that Kinza Kasher of Leoplus USA was chosen as the winner of the Lyfebulb-Celgene 2019 “Addressing Unmet Needs in MS: An Innovation Challenge.”

Leoplus USA is developing Duet, a device and app which aims to support communications between people with MS and their care partners to help improve patients’ disease management outcomes.

“We know communication within families affected by multiple sclerosis can be challenging. Duet is an innovative way to create connections with those you love,” said Tim Coetzee, Ph.D., Chief Advocacy, Services and Research Officer at the National Multiple Sclerosis Society, who served as chair of the judging panel. “We were particularly inspired by Kinza’s love for her mother, which then inspired this unique approach to fostering meaningful conversations and connections.”

An honorable mention was given to Jason DaSilva, the creator of AXS Map, a web platform that allows users to locate, rate and review the accessibility of any location in the world to help MS patients and their care partners facilitate travel.

Ten innovative finalists whose companies are helping to develop potential solutions to address an unmet need in MS were invited to compete at the MS Innovation summit hosted by Lyfebulb and Celgene at Celgene headquarters in New Jersey on June 13. The competition was only open to patient entrepreneurs – those who have been affected by MS as either a patient, loved one or support partner. A diverse panel of judges, which included experts in the MS, healthcare and business communities, selected Kinza as the winner of a $25,000 monetary grant to further develop her proposed potential solution.

“We congratulate each of our patient entrepreneur finalists and Celgene for helping us shine the spotlight on both the issues confronting people affected by multiple sclerosis and the innovative solutions that patient entrepreneurs are developing,” Dr. Karin Hehenberger, CEO and Founder of Lyfebulb. “Additionally, it is highly inspirational to spend two days with such passionate thought leaders in the multiple sclerosis community, from the entrepreneurs to the judges to our host, with stimulating, thought-provoking dialogue around the disease.” The USA based company Celgene Corporation moved with change of 0.07% to $96.51 with the total traded volume of 3144560 shares in recent session versus to an average volume of 6899.47K. The stock was observed in the 5 days activity at 0.49%. The one month performance of stock was 1.63%. CELG’s shares are at 9.10% for the quarter and driving a 24.72% return over the course of the past year and is now at 50.59% since this point in 2018.  Right now the stock beta is 1.52. The average volatility for the week and month was at 0.90% and 0.94% respectively. There are 704.75M shares outstanding and 703.78M shares are floated in market.

Leave a Reply

Your email address will not be published. Required fields are marked *